# A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

> **NCT07708753** · PHASE3 · RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 460 (estimated)

## Conditions studied

- Platinum-resistant Ovarian Cancer
- Platinum-resistant Primary Peritoneal Cancer
- Platinum-resistant Fallopian Tube Cancer

## Interventions

- **DRUG:** SYS6043
- **DRUG:** Liposomal doxorubicin, paclitaxel, or topotecan

## Key facts

- **NCT ID:** NCT07708753
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2029-10-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2026-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07708753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07708753, "A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07708753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*